Lavior Pharma Inc., an International advanced diabetic wound and skincare Company headquartered in Miami, Florida, announced the appointment of Matthew M. Cooper, MD MBA FACS FAsMA FCAMA, to the Company’s Scientific Advisory Board. Dr. Cooper is currently Vice President Medical Affairs, Corporate Health, & Safety at 3M Health Care. He is a board certified Cardiovascular & Thoracic surgeon, a Fellow of the American College of Surgeons (FACS), and has served as Departmental Chair of Surgery and Cardiovascular & Thoracic Surgery at various hospitals. Dr. Cooper has published extensively, is a reviewer for multiple peer reviewed professional journals, and belongs to many professional societies.
Dr. Cooper received his medical degree from the New York University School of Medicine, followed by Residencies and Chief Residencies in General Surgery (New York University Medical Center, The University of Iowa Hospitals & Clinics) and Thoracic Surgery (Columbia Presbyterian Medical Center), a Medical Staff Fellowship in the Surgery Branch of the National Heart, Lung & Blood Institute of the National Institutes of Health (NIH) and a Fellowship in Pediatric Cardiothoracic Surgery at The Hospital for Sick Children, Great Ormond Street, UK. He received his Masters of Business Administration from the Watson Graduate School of Management, Spears School of Business, Oklahoma State University. His research interests have included pioneering methods of immunosuppression for primate cardiac xenograft transplantation, hypertrophic cardiomyopathy, spinal cord protection during thoracoabdominal aortic surgery, and extravascular lung water.
In addition, Dr. Cooper has studied Health Policy at the John F. Kennedy School of Government, and Comprehensive Medical Simulation, both at Harvard University. He is a Senior Aviation Medical Examiner, expert in Aviation Physiology, and a Special Consultant to the Federal Air Surgeon and has been a leader in the application of aviation-based safety culture to health care.
“We extend a warm welcome to Dr. Cooper as he joins our Scientific Advisory Board. As an expert clinician with an extensive and diverse healthcare background as a business executive, Dr. Cooper is a collaborative leader who has deep technical and operational experience in healthcare, business administration, research, and applied innovation. We look forward to his guidance and leadership as Lavior continues to expand its portfolio of innovative and life-changing products across several therapeutic areas,” says Gilad Savion, the CEO and President of Lavior.
Dr. Cooper shares, “I am excited to join Lavior’s Scientific Advisory Board. Lavior’s unique and extremely promising portfiolio of healthcare products continues to gain momentum with clinicians in the US and international markets. I look forward to contributing to their product development and sharing their extensive research and evidence of efficacy with others. Their products are proving to have a major impact on patient outcomes and providing hope for those patients with diabetes.”
About Lavior Pharma Inc.
LAVIOR is the only company exclusively dedicated to the therapeutic diabetes skin care market. The LAVIOR skincare product line soothes and heals some of the most widespread and challenging skin problems – diabetic ulcers, wounds, burns, eczema/atopic dermatitis, bacterial and fungal infections, skin irritations, and cracked skin. LAVIOR’s line of products is based on the proven efficacy of the Inula AGS RIED botanical species. They are developed using the highest quality, pharmaceutical grade ingredients; manufactured and tested to deliver safe, effective, and compliant products. Backed by over 13 years of extensive research and clinical trials, proven clinical safety and efficacy, they consistently outperform conventional treatments.
For more information on Lavior Pharma and its products, please visit www.lavior.com
For Media or other Inquiries, please contact:
Chief Marketing Officer
Phone: (+1) 9178373355